For the quarter ended June 2024, Bruker (BRKR) reported revenue of $800.7 million, up 17.4% over the same period last year. EPS came in at $0.52, compared to $0.50 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $796.23 million, representing a surprise of +0.56%. The company has not delivered EPS surprise, with the consensus EPS estimate being $0.52.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compar ...

文章核心观点 - Bruker Corporation (BRKR)的股票近期期权市场波动较大,暗示投资者预期公司股价将出现大幅波动[1] - 期权隐含波动率高意味着投资者预期公司股价将出现大涨或大跌[2] - 分析师对Bruker公司的评级为中性,最近有1家分析师上调了当季盈利预测,4家下调了预测,整体预测下降[3] 行业和公司研究 行业概况 - Bruker公司所属的仪器仪表行业在Zacks行业排名中位于前43%[3] 公司基本情况 - Bruker公司是一家仪器仪表制造商[3] - 公司目前被评为Zacks Rank 3(中性评级)[3]

Bruker (BRKR) came out with quarterly earnings of $0.52 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.50 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this scientific equipment maker would post earnings of $0.46 per share when it actually produced earnings of $0.53, delivering a surprise of 15.22%.Over the last four quarters, the company has surpassed consensus EPS estimates three times.Bruker, which belon ...

财务业绩 - 第二季度2024年收入为8.007亿美元，同比增长17.4%[5] - 第二季度2024年非GAAP每股收益为0.52美元，同比增长4.0%[8] - 公司将2024财年收入指引提高至33.8-34.4亿美元，同比增长14%-16%[15] - 2024财年非GAAP每股收益预期为2.59-2.64美元[15] - 2024年第二季度和上半年收入分别为8.007亿美元和15.224亿美元，同比增长17.4%和11.4%[50] - 2024年第二季度和上半年GAAP每股收益(摊薄)分别为0.05美元和0.40美元[48] - 2024年第二季度和上半年非GAAP每股收益(摊薄)分别为0.52美元和1.05美元[48] 业务表现 - 第二季度BSI业务收入为7.356亿美元，同比增长19.7%，有机增长8.6%[6] - 第二季度BEST业务收入为6910万美元，同比下降5.0%，有机下降2.8%[6] - 2024年第二季度和上半年Bruker BioSpin、Bruker CALID和Bruker Nano三大业务部门收入均实现同比增长[50] - 2024年第二季度和上半年BEST业务收入同比分别下降3.7%和增长7.4%[60] 利润情况 - 第二季度非GAAP营业利润率为13.8%，同比下降150个基点[7] - 上半年非GAAP营业利润率为13.9%，同比下降390个基点[11] - 2024年第二季度和上半年的非GAAP毛利率和营业利润率[43][39] - 2024年第二季度和上半年的非GAAP净利润和每股收益[42] - 2024年第二季度和上半年的非GAAP税率[41] - 2024年第二季度和上半年的非GAAP利息及其他收支情况[46] 现金流和资产负债 - 2024年第二季度和上半年GAAP经营现金流分别为0.9百万美元和22.7百万美元[49] - 2024年第二季度和上半年非GAAP自由现金流分别为-25.1百万美元和-24.7百万美元[49] - 2024年6月30日和2023年12月31日的资产负债表数据[31][32][33][34][35] - 2024年第二季度和上半年的现金流情况[37] - 2024年第二季度和上半年的资产负债情况[37] - 2024年第二季度和上半年的股本变动情况[37] 增长驱动因素 - 2024年第二季度和上半年有机收入增长分别为7.4%和4.5%[53] - 2024年第二季度和上半年通过收购和内生增长推动了收入的增长[53][56] - 2024年第二季度和上半年美国、欧洲和亚太地区市场收入均实现同比增长[52]

For Immediate ReleaseChicago, IL – August 6, 2024 – Today, Zacks Equity Research discusses Mettler-Toledo International (MTD) and Bruker (BRKR) .Industry: Instruments – ScientificLink: https://www.zacks.com/commentary/2316245/2-instruments-stocks-to-watch-from-a-prospering-industry2 Instruments Stocks to Watch From a Prospering IndustryThe Zacks Instruments - Scientific industry is benefiting from increasing healthcare spending, driven by aging demography, and continued innovation in the pharma and life sci ...

文章核心观点 - 布鲁克公司(Bruker)预计在2024年6月季度报告中将实现营收和利润同比增长 [1] - 实际业绩是否超出预期将是影响公司股价短期走势的关键因素 [2][3] 公司业绩分析 - 预计公司将在下个季度报告中实现每股收益0.52美元,同比增长4% [4] - 预计营收将达7.96亿美元,同比增长16.8% [4] - 分析师近期对公司业绩预期保持稳定,没有大幅调整 [5][6] 业绩预测分析 - 公司最新业绩预测低于共识预期,Earnings ESP为-0.88%,预示可能无法超预期 [12] - 但公司目前评级为中性(Zacks Rank 3),过去4个季度业绩均超预期 [12][14] - 综合来看,很难确定公司是否能够战胜共识业绩预期 [12]

Bruker's (BRKR) strong growth reflects its fundamental commitment to innovate high-value solutions and the ongoing portfolio transformation. Yet, the company’s operations bear the brunt of excessive currency exposure and general macroeconomic headwinds. The stock carries a Zacks Rank #3 (Hold) at present.The CALID segment has been gaining from the strong demand for differentiated instruments, particularly life science mass spectrometry proteomics solutions and optics spectroscopy and microscopy instruments. ...

Bruker’s (BRKR) strong growth reflects its fundamental commitment to innovate high-value solutions and the ongoing portfolio transformation. Yet, the company’s operations are marred by excessive currency exposure and macroeconomic headwinds. The stock carries a Zacks Rank #3 (Hold). Within Bruker’s BSI Nano segment, over the past few quarters, microelectronics and semiconmetrology tools have grown on strong bookings and backlog. The artificial intelligence megatrend is a key factor driving the success of th ...

Business leaders often talk about thinking big. But when it comes to nanotech stocks, the future is all about focusing on the small things. According to the European Commission, nanotechnology represents a scientific and engineering discipline that’s “devoted to designing, producing, and using structures, devices, and systems by manipulating atoms and molecules at nanoscale.” Nanoscales refer to having one or more dimensions of the order of 100 nanometers (or 100 millionth of a millimeter). Stated different ...

Spectronaut® 19 offers significant improvements in identifications, candidate discovery, scalability for large-scale analysis, and support for novel workflows Novel TrueDiscovery® P2 Plasma Enrichment method offers market-leading performance and superior economics for unbiased, deep plasma proteomics New TrueTarget® high-throughput LiP-MS workflow enables large-scale drug target deconvolution screening with improved target identification DigitalProteome™ database and Proteoverse™ data exploration tool help ...